

RETRACTED - Excess mortality among patients with severe mental disorders and effects of communitybased mental healthcare: a community-based prospective study in Sichuan, China

Yaxi Li, Lijing L. Yan, Carine Ronsmans, Hong Wen, Jiajun Xu, Dan Wang and Min Yang

Background

High-quality primary care reduces premature mortality in the general population, but evidence for psychiatric patients in China is scarce.

Aims

To confirm excess mortality in patients with severe mental illness (SMI), and to examine the impact of community-based mental healthcare and other risk factors on their mortality.

Method

We included 93 655 patients in 2012 and 100 706 in 2013 from the national mental health surveillance system in Sichuan, China to calculate the standardised mortality ratio (SMR). A total of 112 576 patients were followed up from 2009 to 2014 for model analyses. We used growth models to quantify the patterns of change for community management measures, high-risk behaviour, disease stability and medication adherence of patients over time, and then used multilevel proportional hazard models to examine the association between change patterns of management measures and mortality.

Results

The SMR was 6.44 (95% CI 4.94–8.26) in 2012 and 7.57 (95% CI 5.98–9.44) in 2013 among patients with SMI aged 15–34 years, and diminished with age. Unfavourable baseline socioeconomic

Background

People with severe mental illness, such as schizophrenia, schizoaffective disorders and bipolar disorder die 10 to 20 years earlier compared with the general population.^{1–3} The mortality rate is two to three times higher than the general population.^{1,2,4} However, most evidence is from high-income countries with better health services and higher health literacy;² the limited studies from low- and middle-income countries suggest a more serious situation. One study from rural Ethiopia reports premature mortality by 30 years for people with severe mental illness,⁴ and three studies from China report a $1.8^{5,6}$ or 4.0^7 times mortality rate for patients who are mentally ill, and the standardised mortality was higher than the general population across the whole lifespan.⁵ However, evidence about mortality rates of patients with mental disorders in China is scant, especially considering the limited geographical coverage of existing data.^{5–7}

The integration of mental health into primary healthcare has been recognised as the most effective approach to closing the gap between need and demand for mental health services in low- and middle-income countries.^{8–10} In 2004, the Chinese government implemented the '686 Program' in certain regions as a pioneering model for comprehensive management and treatment of patients with severe mental illness (SMI).^{11,12} The programme assesses the feasibility of hospital–community integrated services,^{11,12} and prioritises identification and treatment of patients with SMI, especially those with violent tendencies.¹¹ In 2009, the government expanded status increased the hazard of death by 38–50%. Positive changes in high-risk behaviour, disease stability and medication adherence had a 54% (95% Cl 47–60%), 69% (95% Cl 63–73%) and 20% (4–33%) reduction in hazard of death, respectively, versus in those where these were unchanged.

Conclusions

High excess mortality was confirmed among younger patients with SMI in Sichuan, China, Our findings on the relationships between community management and socioeconomic factors and mortality can inform community-based mental healthcare policies to reduce excess mortality among patients with SMI.

Keywords

Severe mental disorder; excess mortality; community-based mental health care; high-risk behaviour; medication adherence.

Copyright and usage

The Author(s), 2021. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/ licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

the '686 Program' by integrating mental healthcare into the primary public health service and scaling up the coverage to almost the whole country.^{12,13} Patients with SMI are diagnosed by psychiatrists and followed up regularly by trained service providers (including psychiatrists, general practitioners or nurses in urban community healthcare centres or rural township hospitals). The programme promotes standard medication, regular physical examinations, health education, rehabilitation and referrals to psychiatrists. A performance evaluation based on 280 000 registered patients in 160 cities in China showed that, from 2006 to 2011, the proportion of patients remaining stable increased significantly from 67.0% to 90.7%, the proportion of aggressive behaviour decreased from 4.8% to 0.5%,11 and a total of 94000 prescriptions of free medication and 12400 sessions of free treatment had been provided.¹⁴ Because of limited resources and a primary concern for social stability,15 the government placed its primary focus on mental illnesses with a high possibility of violent or socially disruptive behaviours.¹³ Thus, six mental disorders with violence tendency - schizophrenia, schizoaffective disorder, delusional disorder, bipolar disorder, psychotic disorder due to epilepsy and disorders of intelectual development with psychosis - are included in the primary mental health services programme.

Community measures and SMI

The government has defined two measures as the performance indicators for the primary mental health programme, disease stability and high-risk behaviour. But little is known about their association with mortality despite the programme being in effect for over 10 years. And medication adherence, which is not under official surveillance but has abundant evidence proving its significance in the treatment of mental illness,¹⁶ is an important process indicator in the programme, with scant research about its association with mortality based on the programme.

Aims

The World Health Organization (WHO) recommends using a multilevel intervention framework (MIF) model, informed by multilevel risk factors for excess mortality in people with SMI at the individual, health system and socio-environment levels, aiming to identify priorities for clinical practice, policy and research.³ Following the MIF model, this study aimed to:

- (a) assess mortality of patients with SMI in Sichuan, China and compare this with the general population;
- (b) examine how progress on three core indicators measuring community-based patients with SMI management i.e. highrisk behaviour, disease stability and medication adherence, is related to mortality; and
- (c) explore other multilevel risk factors.

Method

Data source

Participants were registered patients on the National System of Basic Information Collection and Analysis for Psychoses (NSBICAP) in Sichuan from 1 January 2009 to 31 January 2014. The NSBICAP is the only mental health surveillance system in China,¹⁷ collecting information from patients with SMI on disease stability, violent or socially disruptive behaviours, treatment care (for example taking medication or admission to hospital) and survival status.¹⁷ Sichuan Province is located in southwest China, with a population of over 81 million living in 21 municipalities. There were 158 957 patients registered in the NSBICAP in January 2014, accounting for approximately 20% of the total estimated 800 000 patients with SMI in Sichuan.¹⁸

The recruitment of patients into the NSBICAP includes two pathways: (a) referral from psychiatric hospitals or departments in general hospitals to urban community health centres or rural township hospitals; and (b) direct identification or referral from local communities, community health centres, hospitals, village committees, or the China Disabled Persons' Federation (a national organisation for individuals with disabilities).¹³ Individuals identified from the second pathway are diagnosed by psychiatrists. All participants diagnosed with one of the six specific diseases and with signed informed consent are registered in the NSBICAP, and are managed by doctors or nurses from community health centres or township hospitals.

Once registered, patients are evaluated in terms of high-risk behaviour (harm to people or damage to property), disease stability, mental symptoms and severe physical diseases, social function and adverse drug effects.¹³ They are then followed up at intervals based on their disease stability (stable, more or less stable, or unstable). The frequency for patients who are stable is every 3 months, and every 2 weeks for other patients. At follow-up, each patient is re-evaluated on the same aspects as above, as well as on medication adherence.

The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All procedures involving human patients were approved by the Institutional Review Board at Sichuan University and Mental Health Center of Sichuan Province.

Community management indicators

The three indicators, high-risk behaviour, disease stability and medication adherence, were defined in order to measure community management. All indicators are defined by the Chinese government to assess community-based mental healthcare.¹³ These three measures were assessed at each follow-up for all registered patients and reflect the conditions from the last survey to date.

High-risk behaviour was assessed on a scale of 0 to 5 according to the degree of damage a patient enacted against people or property either verbally or physically, with level 0 indicating no damage at all, and levels 1 to 5 gradually increasing in terms of the degree of damage, as reported by relatives or hospital records from each follow-up. The detailed definition can be found elsewhere¹⁹ and in the Supplementary material 1 available at https://doi.org/10. 1192/bjo.2021.46. This factor was categorised into low risk (level 0–2) and high risk (level 3–5) for this study.


Based on the 2012 Chinese Managerial and Treatment Regulations for Severely Mentally Disordered Patients, disease stability is a comprehensive indicator encompassing assessment of risk behaviour, insight, psychotic symptoms, adverse drug reaction and physical diseases, with the back-up support of psychiatric specialists.^{13,14} At least one psychiatrist would be included in the community management team of each community health centre or township hospital. And a regular top-down on-site instruction from psychiatric specialists to doctors or nurses of community health centres or township hospitals was conducted quarterly. Insight and psychotic symptoms were initially diagnosed by psychiatric specialists following the ICD-10 standards (F20 for schizophrenia, F25 for schizoaffective disorder, F22 for delusional disorder, F31 for bipolar disorder, F06 for psychotic disorder due to epilepsy, and F70-F79 for mental retardation with mental disorders)²⁰ and followed up regularly by trained doctors or nurses.

Adverse drug reactions for patients prescribed medicine by psychiatrists was also collected by the trained doctors or nurses at each follow-up. Physical diseases were diagnosed by licensed doctors. If patients could not continue their work or were incapable of living independently because of physical diseases, they would be considered as having severe physical diseases. Disease stability was categorised into stable and unstable. Stable was defined as high-risk behaviour at level 0 to 2, with complete insight, free of psychotic symptoms, free of serious adverse drug reaction and free of severe physical diseases. Unstable was defined if high-risk behaviour was assessed at level 3 to 5, or if patients had a poor condition in any of the remaining aspects including insight, psychotic symptoms, adverse drug reaction or physical diseases.

Self-reported medication adherence was assessed among those who were prescribed medications to treat mental illnesses (including all medication available to treat mental illnesses, such as antipsychotic and mood stabilising drugs), and was categorised into adherent (taking medicine according to prescription), taking a lower dose of medication or taking it at a reduced frequency than prescribed and refusing to take medicine.

Outcome

Death status at each follow-up was recorded in the NSBICAP, and the date of death of the patient was defined as the survey date when the patient's status was 'died'. We calculated survival time by month from the date of enrolment in the NSBICAP to the date when a 'died' status was recorded, or to the last contact date for those lost to follow-up or censored by 31 January 2014.



Covariates

Based on the MIF model,³ baseline covariates were grouped into five categories. The first category was disorder-specific factors including disease diagnosis, and family history of mental disorders (yes versus no). The second category was socioeconomic position that include education (no formal education or illiterate, primary or middle school, or high school or above), occupation (employed/student/ retired, unemployed, or farmer) and family economic status (poverty versus non-poverty; dichotomised as above or below the poverty line defined by local governments.). The third category was the cultural and societal aspects of ethnicity (Han versus minority). The fourth category was social support, meaning marital status (married versus unmarried). The final category was on health systems and context factors at the county level that consisted of area socioeconomic status (gross domestic product (GDP) per capita, the average figure in 2009, 2011, and 2013 provided by the Health Bureau of Sichuan), the average travelling time to the nearest hospital computed using the topographic data-set of the National Fundamental Geographic Information System of China in 2012,²¹ and the number of mental health hospitals (including psychiatry departments in general hospitals) per 100 000 people. These variables covered 146 counties where participants resided during the study period. Gender and baseline age were other adjustable covariates.

Study population

The study population is shown in Fig. 1. From 1 January 2009 to 31 January 2014, the NSBICAP database registered 158 953 patients with SMI managed by primary health facilities (community health centres and township hospitals). We excluded: (a) 2103 patients with missing values in all three community indicators; (b) 2042 patients with 'logic errors' in the data between dates of birthday, SMI onset and enrolment; (c) 20 626 patients under age 15 years at baseline, as individuals younger than 15 years were unlikely to receive SMI diagnoses.²² A total of 134 182 participants were identified for the current study: 32 392 (24.1%) patients had records for 1 year, 44 282 (33%) for 2 years, 48 978 (36.5%) for 3 years, 8308 (6.2%) for 4 years, and 222 (0.2%) for 5 years.

To compare the disparity of mortality between patients with SMI and the general population, we calculated mortality rates for 93 655 individuals with at least one record in 2012 and 100 706 individuals with at least one record in 2013 (Fig. 1). We did not calculate mortality for 2009, 2010 or 2011 because the mortality rates seemed implausible compared with the general population, possibly because of the early system being unable to cope with data requirements. We did not calculate the death rate for 2014 as only data for January were available.

To examine the association between all-cause mortality and risk factors, of the 134 182 participants aged ≥15 years and registered from January 2009 to January 2014, we further excluded (a) 55 patients from two minority municipalities due to infrequent participation; (b) 21 309 patients who did not have follow-up records for high-risk behaviour, disease stability or medication adherence; (c) 90 patients whose follow-up duration was less than 0.5 month (completed months of follow-up duration were used in the multilevel survival analysis); (d) 152 patients older than 90 years (Fig. 1). Finally, we included 112 576 participants who were registered in 146 out of 183 county-level administrative regions in Sichuan Province. We also conducted a sensitivity analysis excluding those lost to follow-up to estimate the association between community management measures and mortality. To simplify it, we consider participants lost to follow-up if their last contact dates were on or before 31 July 2013 as the longest follow-up interval was 6 months. Of the 112 576 individuals, 88 625 (78.7%) were included in the sensitivity analysis.

Statistical analysis

To answer the first research question, we first calculated the 1-year crude mortality rate of patients with SMI for 2012 and 2013. The numerator was the number of all-cause deaths; the denominator was the total number of registered patients with at least one record subtracting half the number of deaths. We then calculated the age-specific standardised mortality ratio (SMR) and its 95% CI by years with an indirect method, taking the general population of Sichuan Province, obtained from the 2010 census, as the reference population.

For the second and third research questions, we first calculated death rates (defined as number of deaths divided by total follow-up duration, which was person-years) and its 95% CI for patients with different characteristics. Then we used a two-stage modelling approach: growth models in the first stage to identify change in patterns for repeated measures over time, and multilevel proportional hazard models in the second stage to estimate the association between death and the change in patterns for the community measures, as well as other risk factors. Each community management measure was examined separately. In the growth models, with repeated time points at level 1 and individuals at level 2, each patient had a specific linear slope over time. We defined community measures as 'better' in progression in the positive highest third of the slope, and defined measures as 'worse' in progression in the negative lowest third of the slope. Otherwise, the progression was labelled 'no change'. We fitted four separate proportional hazard models for each community measure: we only regressed the progression of the measure in model 1 (minimal model), added the baseline community measure in model 2, added other individual covariates in model 3, and added county-level covariates in model 4 (full model). The effects of covariates in the framework of the MIF model were estimated in the full model. More details about the modelling approach are given in the Supplementary material 2.

We used MLwiN 2.32 to fit the growth models and multilevel models, and Stata 13.0 for the remaining analyses. All estimates were significant at a level of 0.05.

Results

Mortality rate in patients with SMI

The number of deaths among patients with SMI was 1183 in 2012 and 1396 in 2013, with a crude mortality rate of 1.231% (per 1000 persons) and 1.355%, respectively. The average age at death was 60 years (s.d. = 16) in both years. The crude mortality rate for males was 1.364% (636 deaths) in 2012 and 1.534% (765 deaths) in 2013; for females, it was 1.106% (547 deaths) and 1.187% (631 deaths), respectively.

The SMR was 6.44 (95% CI 4.94–8.26) in 2012 and 7.57 (95% CI 5.98–9.44) in 2013 for those aged 15–34 years; 3.60 (95% CI 3.08–4.18) in 2012 and 3.70 (95% CI 3.19–4.27) in 2013 among those aged 35–44 years; and overall 1.35 (1.28–1.43) in 2012 and 1.50 (1.42–1.58) in 2013 for all patients aged \geq 15 years, respectively

(Table 1). The SMR decreased dramatically with age, to 0.82 (95% CI 0.72–0.93) in 2012 and 0.86 (0.76–0.97) in 2013 among patients aged \geq 75 years. Male patients aged 35–74 years in 2012, or aged 15–74 years in 2013, had higher standardised mortality rates than female patients, thus leading to an overall higher SMR.

Characteristics of patients and counties in modelling analysis

Among the 112 576 patients with SMI used for model analysis (Fig. 1), 1987 (11.0 per 1000 person-years) died from 2009 to 2014. The median survival time was 20 months (interquartile (IQR) = 12-26 months). The mean baseline age for all participants was 49 years (s.d. = 14 years, Table 2). Nearly half of the participants (54 814, 48.7%) were male.

The proportions of 'better' for high-risk behaviour (29.1%) and disease stability (26.8%) were similar. However, for only 14.2% of patients was there an improvement in terms of medication adherence; patients' medication adherence got worse in 18.1%; which was higher than rates of deterioration for high-risk behaviour (1.9%) and disease stability (4.6%) (Table 2). Participants with better progression for the measures of high-risk behaviour, disease stability and medication adherence showed the lowest death rates, however, those with worse progression did not have higher death rates compared with those where it was unchanged.

Those patients with an unfavourable baseline status on all three measures had higher death rates than those with a favourable status, as expected. Most patients (89%) were diagnosed with schizophrenia. The death rates were higher among males, patients with no family history of mental disorders, with lower education attainment, those working as farmers and unmarried compared with their counterparts. Of the 146 counties, GDP per capita varied from \$7265 to \$78 914 (RMB, Chinese currency), the average travelling time to the nearest hospital varied from 13.8 min to 180.6 min, and the number of mental health-related hospitals from 0 to 1.01 per 100 000 population.

Association between death and risk factors

High-risk behaviour

In the full model, participants with better progression regarding high-risk behaviour showed a 54% (95% CI 47–60%) lower hazard of death than those unchanged (Table 3). People with worse progression on measures did not show a difference from the reference

Study year, age group in years	Male			Female			Total		
	Deaths, <i>n</i>	Registered patients, <i>n</i>	SMR (95% CI)	Deaths, <i>n</i>	Registered patients, <i>n</i>	SMR (95% CI)	Deaths, <i>n</i>	Registered patients, <i>n</i>	SMR (95% CI)
2012									
15–34	34	6590	6.34 (4.39-8.86)	28	5247	6.56 (4.36–9.48)	62	11 837	6.44 (4.94-8.2
35–44	108	13 250	4.27 (3.51–5.16)	63	11 665	2.83 (2.17–3.62)	171	24 915	3.60 (3.08-4.1
45–54	98	10 679	2.32 (1.88–2.82)	76	10 589	1.81 (1.43–2.27)	174	21 268	2.06 (1.77–2.4
55–64	165	10 053	1.95 (1.67–2.28)	132	12 910	1.21 (1.02–1.44)	297	22 963	1.54 (1.37–1.7
65–74	141	4823	1.35 (1.13–1.59)	103	6749	0.70 (0.57–0.85)	244	11 572	0.97 (0.85–1.1
≥75	90	1563	0.82 (0.66–1.01)	145	2549	0.81 (0.69–0.96)	235	4112	0.82 (0.72-0.9
Total	636	46 958	1.71 (1.58–1.85)	547	49 709	1.09 (1.00–1.18)	1183	96 667	1.35 (1.28–1.4
2013									
15–34	50	7070	8.70 (6.46–11.47)	28	5612	6.13 (4.08–8.87)	78	12 682	7.57 (5.98–9.4
35–44	118	14 085	4.39 (3.64–5.26)	70	12 510	2.93 (2.28–3.70)	188	26 595	3.70 (3.19–4.2
45–54	144	11 610	3.14 (2.65–3.69)	73	11 501	1.60 (1.25 (2.01)	217	23 111	2.37 (2.07-2.7
55–64	204	10729	2.27 (1.97-2.60)	154	13 850	1.32 (1.12–1.55)	358	24 579	1.73 (1.56–1.9
65–74	149	5153	1.33 (1.13–1.56)	148	7319	0.93 (0.78–1.09)	297	12 472	1.09 (0.97–1.
≥75	100	1617	0.89 (0.72-1.08)	158	2696	0.84 (0.71–0.98)	258	4313	0.86 (0.76–0.9
Total	765	50 264	1.95 (1.81–2.09)	631	53 488	1.17 (1.08–1.27)	1396	103 752	1.50 (1.42-1.5

	Death rate (95% Cl, pe				
Characteristics	Value (<i>n</i> = 112 576)	1000 person-years)	Deaths, $n (n = 19)$		
	Value (// = 112 5/8)	1000 person-years)			
Gender, <i>n</i> (%)			1101		
Male	54 814 (48.7)	12.6 (11.9–13.4)	1101		
Female	57 762 (51.3)	9.6 (9.0–10.2)	886		
ge at baseline, mean (s.d.)	49.0 (13.9)	11.0 (10.6–11.5)	1987		
ndicators of community-based mental healthcare, n (%)					
rogression of high-risk behaviour					
No change	77 609 (68.9)	14.2 (13.5–14.9)	1586		
Better	32 782 (29.1)	5.4 (4.9–6.0)	352		
Worse	2185 (1.9)	12.6 (9.5–16.7)	49		
aseline high-risk behaviour					
Low risk	108 421 (96.3)	10.9 (10.4–11.4)	1888		
High-risk	4155 (3.7)	13.7 (11.2–16.7)	99		
ogression of disease stability					
No change	77 244 (68.6)	14.9 (14.2–15.7)	1607		
Better	30 207 (26.8)	4.3 (3.8–4.8)	269		
Worse	5125 (4.6)	11.5 (9.6–13.9)	111		
aseline disease stability	5125 (4.0)	11:3 (7:0-13:7)	111		
	102 210 (01 8)	100 (10 4 11 4)	1001		
Stable	103 310 (91.8)	10.9 (10.4–11.4)	1801		
Unstable	9266 (8.2)	12.2 (10.6–14.1)	186		
rogression of medication adherence					
No change	76 233 (67.7)	12.2 (11.6–12.9)	1408		
Better	15 962 (14.2)	8.5 (7.5–9.7)	242		
Worse	20 381 (18.1)	9.2 (8.3–10.3)	337		
aseline medication adherence					
Adherent	39 136 (34.8)	8.3 (7.7–9.1)	523		
Taking reduced doses of medicine or taking it at a reduced	33 533 (29.8)	11.4 (10.6–12.4)	646		
frequency than prescribed					
Refusing to take medicine	39 907 (35.5)	13.4 (12.6–14.4)	818		
isorder-specific factors, n (%)					
iagnose					
Schizophrenia	100 482 (89.3)	11.0 (10.5–11.5)	1791		
Schizoaffective disorder	1647 (1.5)	10.3 (7.0–15.3)	25		
Paranoiac psychosis	361 (0.3)		11		
	2999 (2.7)	18.5 (10.3–33.4)			
Bipolar affective disorder		10.3 (7.7–13.7)	47		
Psychotic disorder due to epilepsy	3266 (2.9)	13.4 (10.5–17.1)	65		
Disorders of intellectual development with psychosis	3821 (3.4)	9.6 (7.2–12.8)	48		
amily history of mental disorders					
No	108 076 (96.0)	11.1 (10.6–11.6)	1921		
Yes	4500 (4.0)	9.1 (7.2–11.6)	66		
pcioeconomic position, n (%)					
ducation					
High school or above	7452 (6.6)	5.3 (4.1–6.8)	63		
Primary or middle school	66 402 (59.0)	9.1 (8.5–9.7)	967		
No formal education or illiterate	32 260 (28.7)	16.2 (15.1–17.3)	836		
Unknown ^a	6462 (5.7)	12.1 (10.1–14.4)	121		
ccupation	0.02 (0.7)	12.1 (10.1 11.1)			
Employed ^b –students or retired	3405 (3.0)	8.4 (6.2–11.2)	45		
Unemployed	6968 (6.2)	9.9 (8.2–11.9)	110		
Farmer ^c	88 493 (78.6)				
		11.6 (11.1–12.2)	1665		
Unknown ^a	13710 (12.2)	8.1 (7–9.5)	167		
conomic status ^d					
Non-poverty	19 471 (17.3)	11.0 (9.9–12.2)	344		
Poverty	67 300 (59.8)	11.6 (11.0–12.3)	1259		
Unknown ^a	25 805 (22.9)	9.5 (8.6–10.5)	384		
ultural and societal factor, n (%)					
thnicity					
Han	112 109 (99.6)	11.0 (10.6–11.5)	1979		
Minority	467 (0.4)	12.0 (6.0–24.0)	8		
pcial support, n (%)			5		
arital status					
Married	68 777 (61.1)	10.3 (9.7–10.9)	1134		
Unmarried ^e					
	39 231 (34.9)	12.4 (11.6–13.3)	780		
Unknown ^a	4568 (4.1)	10.4 (8.3–13.1)	73		

a. Unknow was included in the model analysis.
b. Including professional/technical personnel, managerial personnel, industrial worker.
c. Including agriculture, forestry, animal husbandry, fishery.
d. Determined by whether they were above or below the poverty line as determined by the local government according to the local socioeconomic status.
e. Including widowed, separated, divorced and never married.

	Model 1 ^a	Model 2 ^b	Model 3 ^c	Model 4 ^d
High-risk behaviour				
Progression of high-risk behaviour, HR (95% CI)				
No change	Ref.	Ref.	Ref.	Ref.
Better	0.49 (0.43-0.54)	0.44 (0.39-0.50)	0.46 (0.39–0.53)	0.46 (0.40-0.5
Worse	1.04 (0.72–1.5)	0.81 (0.55–1.19)	0.84 (0.52-1.35)	0.84 (0.53–1.3
Baseline high-risk behaviour, HR (95% CI)				
High risk	-	Ref.	Ref.	Ref.
Low risk	-	0.44 (0.33-0.59)	0.42 (0.3-0.6)	0.41 (0.29-0.5
Variance (county), estimate (s.e.)	0.368 (0.062)	0.371 (0.063)	0.348 (0.067)	0.342 (0.066)
Disease stability				
Progression of disease stability, HR (95% CI)				
No change	Ref.	Ref.	Ref.	Ref.
Better	0.39 (0.34-0.44)	0.31 (0.27–0.36)	0.31 (0.27–0.37)	0.31 (0.27-0.3
Worse	1.01 (0.78–1.29)	0.9 (0.69–1.18)	0.93 (0.67-1.28)	0.94 (0.68-1.2
Baseline disease stability, HR (95% CI)				
Unstable	-	Ref.	Ref.	Ref.
Stable	-	0.43 (0.35–0.53)	0.43 (0.34–0.56)	0.43 (0.33-0.5
Variance (county), estimate (s.e.)	0.321 (0.057)	0.331 (0.059)	0.315 (0.063)	0.308 (0.062)
Medication adherence				
Progression of medication adherence, HR (95% CI)				
No change	Ref.	Ref.	Ref.	Ref.
Better	0.79 (0.69-0.91)	0.71 (0.61–0.82)	0.81 (0.68–0.97)	0.80 (0.67-0.9
Worse	0.83 (0.73-0.95)	0.96 (0.84-1.10)	0.89 (0.75-1.05)	0.89 (0.76-1.0
Baseline medication adherence, HR (95% CI)			(
Adherent	-	Ref.	Ref.	Ref.
Taking reduced doses of medicine or taking it at a reduced frequency than	_	1.54 (1.35–1.75)	1.24 (1.06-1.46)	1.25 (1.06-1.4
prescribed				
Refusing to take medicine	_	1.61 (1.42–1.83)	1.02 (0.87–1.2)	1.02 (0.87–1.2
Variance (county), estimate (s.e.)	0.318 (0.055)	0.307 (0.054)	0.28 (0.055)	0.283 (0.056)
 kef, reference. Without adjusting for covariates. Adjusting for baseline community management indicator. Adding other individual covariates, including age at baseline, gender, diagnose, family history narital status. Adding county-level covariates, including gross domestic product per capita, average travelli 				

group. Favourable baseline status was associated with a 59% (95% C41–71%) lower hazard of death than the unfavourable status.

Disease stability

Participants who showed improvement in disease stability had a consistently lower hazard of death compared with those patients where it was unchanged, with a 69% (95% CI 63–73%) reduced hazard in the full model (Table 3). Patients with worse progression showed no difference from the reference. Stable baseline disease status was associated with a 57% (95% CI 45–67%) lower hazard of death than the unstable status.

Medication adherence

Participants with improvement in medication adherence showed a 20% (95% CI 4–33%) lower hazard of death compared with the unchanged group (Table 3). Those getting worse showed no difference from their counterparts. Compared with participants who were adherent at baseline, people taking a lower dose of their medication or taking it less frequently than prescribed had a 25% (95% CI 6–46%) higher hazard of death. Surprisingly, patients refusing to take medicine did not show a greater hazard of death in the fully adjusted model.

In the sensitivity analysis excluding those lost to follow-up, similar results can be found in Supplementary Table 1.

Other risk factors

Effects of other risk factors on risk of death were similar based on the three full models (Supplementary Table 2). Disadvantaged socioeconomic status, such as lower education level, unemployment and farmer, was associated with a 38–50% higher hazard of death. Less social support, i.e., unmarried, was associated with a 32% higher hazard compared with married status. None of the health systems and context factors had a significant impact on risk of death in all models.

Discussion

Main findings

Using a large provincial sample of community-dwelling participants with SMI in Sichuan, China, we found that the SMRs were 6.44 and 7.57 times higher than the general population in patients aged 15–34 years in 2012 and 2013, respectively, and the mortality gap diminished with age. Participants whose risk behaviour, disease stability and medication adherence improved over time had a 54%, 69% and 20% reduction in the hazard of death, respectively, even after controlling six components of the multilevel risk factor model for excess mortality in people with SMI.³ Favourable baseline status of all three community indicators was related to a reduced hazard of 25–59%. Disadvantaged socioeconomic status and less social support were associated with a 32–50% higher hazard of death.

Comparison with findings from other studies

Our findings echo numerous studies that have found that people with mental illness have higher mortality than the general population, including three studies conducted with Chinese participants.⁵⁻⁷ Systematic reviews have reported two to three times mortality for SMI,^{1,23} and the mortality gap tended to diminish with increasing age,^{5,24} consistent with our findings. Older adults experienced slightly higher SMRs from natural causes than people

aged 20–39 years, while younger adults had remarkably higher SMRs from unnatural causes such as poisoning and suicide, especially among women.²⁵ The age diminution in China needs further investigation for the age-cause-specific causes of death.

The SMRs in our study (overall 1.35 and 1.5) suggest lower excess risks compared with the above findings (1.8-4.0),^{1,5-7,22} which could be explained by the following:

(a) In China, 22% patients with mental illness had ever sought professional care, only 12% had ever been admitted to a psychiatric hospital. The care-seeking rate for older adults was lower than younger people with a larger gap among those with severer disability.²⁶ Using data from the Sichuan NSBICAP, one study reported that fewer than 1.2% of patients who died had received any treatment before death.¹⁸ However, because the identification of patients included referral or direct identification from institutions, patients with severe symptoms and limitation of motion, especially older adults, might well be omitted and excluded from the system. The SMR for patients aged 15–64 was 2.26, similar to the Nordic²⁷ and Tunisian²⁴ studies. The mortality rate for patients aged 65 and above may be underestimated because of the lower care-seeking rate discussed above.

(b) Evidence using in-patient data might overestimate mortality in people with mental disorders, as patients in hospitals are more likely to have serious conditions than patients who are community dwelling.²⁸

Our findings show a notable positive association between improvement in risk behaviour, disease stability or medication adherence and a decreased hazard of death. High-risk behaviour, including violence against others or self, often implies deterioration of symptoms and lack of insight into psychotic symptoms and thus worse adherence to treatment,²⁹ which would aggravate disease symptoms and increase risk of death. Stereotypes of individuals with mental illness being violent would deepen the stigma that permeates patients' lives,³⁰ contributing to them neglecting routine health checks and refusing necessary healthcare²

Although it has a strong association with mortality, disease stability may not be an efficient measure in predicting mortality for this particular population because of its inability to distinguish mental and physical symptoms. Rigorously designed indicators tested for validity and reliability are necessary for further promotion and dissemination of mental healthcare. Numerous studies highlight the beneficial impact of medication adherence on health outcomes.^{2,33} Poor adherence to treatment is associated with worse symptoms of mental illness, increased risk of readmission, relapse and mortality.³³ Using the same database, Tang and colleagues³⁴ reported an unchanged rate of medication adherence from 2006 to 2013, compared with risk behaviour and disease stability, which improved significantly over time. Although medication adherence may be overestimated in our study and in Tang and colleagues' study because long-acting injectable antipsychotics were included (and the proportion was unknow), its relationship with death may not be biased. Thus, we recommend the government and health professionals to focus on process indicators in the performance assessment of mental healthcare.

As expected, lower socioeconomic status was associated with increased hazard of death resulting from disparities in health resources and health literacy.³⁵ The literature has consistently identified that married individuals generally report better health and lower mortality compared with unmarried ones, partially benefiting from spousal emotional support.³⁶ Social determinants of health, such as poverty and connectedness, most likely interact with disease characteristics, behavioural and lifestyle factors, and health services to determine the differential mortality found in people with mental disorders.²³

Strengths and limitations

There are several strengths to our study. We are among the first to study the association between community management measures and mortality among patients with SMI under the administrative surveillance system in China. Community mental healthcare in China is responding to the international call to integrate clinical treatment with primary care, thus it is critical to assess the value of these key measures, which may prompt the development of community-based mental health services.

Second, we used a two-stage model including growth models and multilevel models, effectively linking the changes in patterns of the key indicators and the risk factors for mortality. The growth model can handle repeated measures with random missing data and irregular time intervals between measures (for example medication adherence was assessed at irregular times), ideal for our data. The multilevel model is designed to handle the hierarchical data to mitigate type I error for the estimation of predictors' coefficients by extracting different levels' variances.

Third, we followed the MIF model to estimate risk factors for mortality among patients with SMI, providing insight into identifying priorities of interventions under a systematic framework. Finally, we used the NSBICAP, the only mental health surveillance system in China, for comprehensive analyses for a whole province, which provides evidence for comparison with other areas with a different context.

We acknowledge several limitations, primarily the short length of follow-up because of the limited accessibility of administrative data and the lack of evaluation studies for the quality of the dataset.¹² We excluded data collected before 2009, and only calculated mortality for 2012 and 2013, as the early system might have resulted in lower quality data. A system review has demonstrated that studies with shorter follow-up tended to report higher mortality ratios.²³ Further studies with longer follow-up durations should be developed to test our methods and findings.

As our study used large scale and routinely collected administrative data, the quality of data can always be debated. We conducted strict inclusion and exclusion criteria for data cleaning and analysed the logical rationality of time-related variables, and excluded those with missing records, those with logic errors, those under 15 years old at baseline, and those without follow-up records in the final analysis. This procedure might lead to a biased sample of patients with mental illness in Sichuan Province. However, it is less likely to affect the association between progress of community management measures and mortality of patients.

Furthermore, the mortality of older adults in this paper could be underestimated, although it was claimed that over 20% of the estimated patients with SMI were registered in the system by the end of 2013.¹⁸ As explained above, because recruitment relied largely on referral from institutions, and older adults were more unlikely to receive any professional services before death,²⁶ the representativeness of the data is debatable, and the mortality and SMR estimated in this study may not represent the actual mortality of community-based patients with SMI in Sichuan. However, this may not affect the results in the association analysis.

Another limitation is that the information about death in the NSBICAP was obtained through regular follow-up by community workers. Neither the dates nor the specific causes of death were collected by the system. In this study, we used the survey dates as a proxy of date of death when calculating survival time. The survival time for the deceased might be slightly overestimated because their actual date of deaths were supposed to be two weeks to six months (depend on their follow-up frequency) earlier than the last survey dates. As a consequence, the association between community measures and mortality may be slightly underestimated.

In addition, although the growth model has obvious advantages in dealing with irregular time points and creating a specific slope for each individual, we manually divided the patterns of change using a tertile method after trying different strategies (for example quartile, quintile, decile) per overall consideration of the fitness effects and the number of participants in each group. This approach is popular in social science but the results need more verification using different data. Finally, we have pooled all disorders together in the analysis, irrespective of their differences in terms of disease characteristics, treatment and thus their association with death.

Implications

In this large community-based mental health programme in China, we have evidenced the effectiveness of three key community measures in evaluating a community-based mental health outcome survival - among patients with SMI. Over time the management strategy for these patients with targeting reducing high-risk behaviour, increasing stability of both mental and physical diseases, and increasing medicine adherence could lead to reduced mortality in patients. In place for over 10 years as the world-largest mental health services demonstration project,³⁷ this programme has scant evidence evaluating its project design and the effectiveness of the indicators that are being monitored. Our findings are of great importance in filling this gap. As the integration of mental health into primary care is a major pragmatic method advocated by the World Health Organization, particularly for low- and middleincome countries with limited health resources, this study provides some innovative evidence on the rationality of a national community-management programme, and may facilitate sustained evidence-based mental healthcare programmes for other counties with limited health resources.

Yaxi Li, MM, West China School of Public Health, Sichuan University, China; Global Heath Research Center, Duke Kunshan University, China; Lijing L. Yan, PhD, Global Heath Research Center, Duke Kunshan University, China; Global Heath and Development, Peking University, China; The George Institute for Global Heath at Peking University Health Science Center, China; and Department of Preventive Medicine Feinberg School of Medicine, Northwestern University, USA; Carine Ronsmans, PhD, Faculty of Epidemiology and Population Health, Department of Infortious Disease Epidemiology, London School of Hygiene and Tropical Medicine, LK, Hong Wen, BM, The Third Hospital of Mianyang, China; Jiajun Xu, PhD, West China Hospital, Sichuan University, China; Dan Wang, MM, The Third Hospital of Mianyang, China, Min Yang D, MPH, West China School of Public Health, Sichuan University, China; and Faculty of Health, Art and Design, Swinburne University of Technology, Australia

i.cn

Correspondence: Min Yang. Email: yangmi

First received 15 Aug 2020, final revision 8 Mar 2021, accepted 23 Mar 2021

Supplementary material

Supplementary material is available online at https://doi.org/10.1192/bjo.2021.46.

Data availability

The publication of data is not permitted according to government regulations. All information that could be used to identify personal identities, including names, ID number and addresses has been concealed before we gained access to the data. However, anonymised data might be available upon request.

Acknowledgements

The publication is based on data collected by hundreds of mental health professionals in communities. We acknowledge and thank them for managing the information.

Author contributions

Y.L. conducted the literature review, analysed the data and drafted and revised the manuscript. L.L.Y., C.R., and J.X. contributed to the study design and the results interpretation, and reviewed the manuscript. H.W. and D.W. supervised the collection and the quality control of the data, and contributed to the results interpretation. M.Y. was the Grant principal investigator, designed the study, supervised data analysis, contributed to the results interpretation, and reviewed the manuscript. All authors read and approved the final version of the submission.

Funding

This work was supported by the China Medical Board (Grant number CMB 12-106). The funder had no role in study design, data collection, data analysis, data interpretation or writing of the report.

Declaration of interest

None

References

- Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry 2014; 13: 153–60.
- 2 World Health OrganizationHeadquarters. *Meeting Report on Excess Mortality in Persons with Severe Mental Disorders*. WHO, 2015.
- 3 Liu NH, Daumit GL, Dua T, Aquila R, Charlson F, Cuijpers P, et al. Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas. *World Psychiatry* 2017; 16: 30–40.
- 4 Fekadu A, Medhin G, Kebede D, Alem A, Cleare AJ, Prince M, et al. Excess mortality in severe mental illness: 10-year population-based cohort study in rural Ethiopia. *Br J Psychiatry* 2015; **206**: 289–96.
- 5 Zhou B. Retrospective analysis of life expectance of patients with mental illness in Shanghai Pudong New Area Iin Chinese]. Shanghai Archives of Psychiatry 2010; 4: 224-6.
- 6 Zhang T, Wang H, Li M, Yang J, Zheng W. Three-year death status and causes of schizophrenia in Baoshan city [in Chinese]. *Chin J Prev Contr Chron Dis* 2015; 23: 198–201
- Ran MS, Chen EY, Conwell Y, Chan CL, Yip PS, Xiang MZ, et al. Mortality in people with schizophrenia in rural China: 10-year cohort study. *Br J Psychiatry* 2007; **190**: 237–42.
- 8 World Health Organization. World Organization of Family Doctors. Integrating Mental Health into Primary Care: A Global Perspective. WHO, 2008.
- 9 Saraceno B, van Ommeren M, Batniji R, Cohen A, Gureje O, Mahoney J, et al. Barriers to improvement of mental health services in low-income and middle-income countries. *Lancet* 2007; 370: 1164–74.
- 10 Kauye F, Chiwandira C, Wright J, Common S, Phiri M, Mafuta C, et al. Increasing the capacity of health surveillance assistants in community mental health care in a developing country, Malawi. *Malawi Med J* 2011; 23: 85–8.
- 11 Ma H, Liu J, He Y, Xie B, Xu Y, Hao W, et al. An important pathway of mental health service reform in China: introduction of 686 Program. *Chin Ment Health J* 2011; 25: 725–9.
- 12 Liang D, Mays VM, Hwang WC. Integrated mental health services in China: challenges and planning for the future. *Health Policy Plan* 2018; 33: 107–22.
- 13 Ministry of Health of the People's Republic of China. *Chinese Managerial and Treatment Regulations for Severely Mentally Disordered Patients* [in Chinese]. Ministry of Health of the People's Republic of China, 2012.
- 14 Ma H. Integration of hospital and community services-the '686 Project' is a crucial component in the reform of China's mental health services. Shanghai Arch Psychiatry 2012; 24: 172–4.
- 15 Liu J, Ma H, He YL, Xie B, Xu YF, Tang HY, et al. Mental health system in China: history, recent service reform and future challenges. *World Psychiatry* 2011; 10: 210–6.
- 16 Chapman SC, Horne R. Medication nonadherence and psychiatry. Curr Opin Psychiatry 2013; 26: 446–52.
- 17 Zhou W, Xiao S. Reporting on China's mental health surveillance. Am J Psychiatry 2015; 172: 314–5.
- 18 Wen H, Wang D, Wang W, Yang X. The state of death and the cause of death in severe psychotic patients who were managed in Sichuan, 2011–2013 [in Chinese]. Sichuan Ment Health 2014; 27: 337–40.
- 19 Liu Y, Liu X, Wen H, Wang D, Yang X, Tang W, et al. Risk behavior in patients with severe mental disorders: a prospective study of 121,830 patients managed in rural households of western China. *BMC Psychiatry* 2018; 18: 134.
- 20 Jingwu Dong (trans.). The ICD-10 International Statistical Classification of Diseases and Related Health Problems (2nd ed). People's Medical Publishing House, 2008.
- 21 Pan J, Liu H, Wang X, Xie H, Delamater PL. Assessing the spatial accessibility of hospital care in Sichuan Province, China. Geospat Health 2015; 10: 384.
- 22 Chang CK, Hayes RD, Perera G, Broadbent MT, Fernandes AC, Lee WE, et al. Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London. *PLoS One* 2011; 6: e19590.

- 23 Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry 2015; 72: 334–41.
- 24 Zgueb Y, Jomli R, Ouertani A, Hechmi S, Ouanes S, Nacef F, et al. Deaths in a Tunisian psychiatric hospital: an eleven-year retrospective study [in Chinese]. Encephale 2014; 40: 416–22.
- 25 Heiberg IH, Jacobsen BK, Nesvag R, Bramness JG, Reichborn-Kjennerud T, Naess O, et al. Total and cause-specific standardized mortality ratios in patients with schizophrenia and/or substance use disorder. *PLoS One* 2018; **13**: e0202028.
- 26 Phillips MR, Zhang J, Shi Q, Song Z, Ding Z, Pang S, et al. Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001–05: an epidemiological survey. *Lancet* 2009; 373: 2041–53.
- 27 Wahlbeck K, Westman J, Nordentoft M, Gissler M, Laursen TM. Outcomes of Nordic mental health systems: life expectancy of patients with mental disorders. Br J Psychiatry 2011; 199: 453–8.
- 28 Crump C, Ioannidis JP, Sundquist K, Winkleby MA, Sundquist J. Mortality in persons with mental disorders is substantially overestimated using inpatient psychiatric diagnoses. J Psychiatr Res 2013; 47: 1298–303.
- 29 Arango C, Calcedo Barba A, Gonzalez S, Calcedo Ordonez A. Violence in inpatients with schizophrenia: a prospective study. *Schizophr Bull* 1999; 25: 493–503.
- 30 Webermann AR, Brand BL. Mental illness and violent behavior: the role of dissociation. Borderline Personal Disord Emot Dysregul 2017; 4: 2.

- 31 Saxena S. Excess mortality among people with mental disorders: a public health priority. Lancet Public Health 2018; 3: E264–5.
- 32 Sampson S, Mansour M, Maayan N, Soares-Weiser K, Adams CE. Intermittent drug techniques for schizophrenia. *Cochrane Database Syst Rev* 2013; 7: CD006196.
- 33 Garcia S, Martinez-Cengotitabengoa M, Lopez-Zurbano S, Zorrilla I, Lopez P, Vieta E, et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol 2016; 36: 355–71.
- 34 Tang W-W, Liu Y-Y, Cao X, Li Y-X, Wen H, Wang D, et al. Does community management for patients with severe mental disorders have any effects? An evaluation study based on 134 742 patients in western China. *Lancet* 2019; 394 (suppl 1): S2.
- 35 Berkman ND, Sheridan SL, Donahue KE, Halpern DJ, Crotty K. Low health literacy and health outcomes: an updated systematic review. Ann Intern Med 2011; 155: 97–107.
- 36 Robards J, Evandrou M, Falkingham J, Vlachantoni A. Marital status, health and mortality. *Maturitas* 2012; 73: 295–9.
- 37 Good BJ, Good MJ. Significance of the 686 Program for China and for global mental health. Shanghai Arch Psychiatry 2012; 24: 175–7.

OPEN ACCESS (†)

TRA NTENT